drugset / Trial / NCT00128440
High Dose Trial in COPD
RandomizedCrossoverDouble-blindTreatment
Summary
The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients with COPD.
Timeline
- Start
- 2005-08
- Primary completion
- 2006-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEA 2180 BR | Unknown | 200 ug | Inhaled |
| Subject | BEA 2180 BR | Unknown | 400 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 5 ug | Inhaled |